Revance Therapeutics Inc (RVNC) concluded trading on Thursday at a closing price of $3.06, with 3.29 million shares of worth about $10.08 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 14.18% during that period and on Thursday the price saw a gain of about 0.66%. Currently the company’s common shares owned by public are about 104.90M shares, out of which, 95.30M shares are available for trading.
Stock saw a price change of -0.65% in past 5 days and over the past one month there was a price change of -17.96%. Year-to-date (YTD), RVNC shares are showing a performance of 0.66% which decreased to -67.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.30 but also hit the highest price of $9.74 during that period. The average intraday trading volume for Revance Therapeutics Inc shares is 2.49 million. The stock is currently trading -4.43% below its 20-day simple moving average (SMA20), while that difference is down -24.73% for SMA50 and it goes to -28.36% lower than SMA200.
Revance Therapeutics Inc (NASDAQ: RVNC) currently have 104.90M outstanding shares and institutions hold larger chunk of about 80.76% of that.
The stock has a current market capitalization of $319.44M and its 3Y-monthly beta is at 0.86. It has posted earnings per share of -$1.92 in the same period. It has Quick Ratio of 3.05. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RVNC, volatility over the week remained 0.92% while standing at 2.25% over the month.
Stock’s fiscal year EPS is expected to rise by 42.40% while it is estimated to increase by 38.87% in next year. EPS is likely to grow at an annualized rate of 11.60% for next 5-years, compared to annual growth of 0.57% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on January 29, 2024 offering a Neutral rating for the stock and assigned a target price range of between $16 and $9 to it. Coverage by Goldman stated Revance Therapeutics Inc (RVNC) stock as a Neutral in their note to investors on January 09, 2024, suggesting a price target of $8 for the stock. On August 16, 2023, Exane BNP Paribas Upgrade their recommendations, while on October 11, 2022, Morgan Stanley Initiated their ratings for the stock with a price target of $27. Stock get a Buy rating from Goldman on September 22, 2022.
